|Bid||3.50 x 1000|
|Ask||5.00 x 1100|
|Day's Range||4.42 - 4.56|
|52 Week Range||4.18 - 11.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.83|
If left untreated, sleep loss can result in serious medical consequences. A leading cause of sleep loss is a medical condition called nocturia,1 which a staggering 72 percent of Americans have never heard about, according to a new national online survey of 2,040 U.S. adults conducted by The Harris Poll, and endorsed by Caregiver Action Network, National Association for Continence, Prostate Conditions Education Council, and The Simon Foundation for Continence. Nocturia forces individuals to get up more than once per night to urinate.
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Warning! GuruFocus has detected 8 Warning Signs with PFE. The value investing firm has been building its stake in Avadel as the company's stock price has declined.
Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Executive Officer, Mike Anderson, will present at the 2018 Wells Fargo Healthcare Conference in Boston on Thursday, September 6, 2018 at 3:40 pm EDT.
Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, presented new findings today from Phase III clinical trials of AV002 at the International Continence Society (ICS) Meeting in Philadelphia. The data demonstrate nocturia patients treated with AV002 – NOCTIVA™ (desmopressin acetate) Nasal Spray, an emulsified microdose of desmopressin – had a significant reduction in the number of nocturic voids (NOV) among older adults, a longer first uninterrupted sleep period (FUSP) at night, rapid efficacy responses after one dose and a well-tolerated safety profile. The abstracts were entitled, “Extended first uninterrupted sleep period for older adults following treatment with AV002, an emulsified microdose vasopressin analog,” and “Rapid nocturia efficacy of AV002, an emulsified microdose vasopressin analog,” and were presented by Benjamin M. Brucker, M.D., urologist and director of the Center of Female Pelvic Medicine at New York University’s Langone Health and Diane K. Newman, DNP, FAAN, co-director of Penn Center for Continence and Pelvic Health, respectively.
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Avadel Pharmaceuticals PLC Sponsored ADR (NASDAQ: AVDL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at ...
On a per-share basis, the Dublin-based company said it had a loss of 9 cents. The specialty pharmaceutical company posted revenue of $29.2 million in the period. Avadel shares have declined 27 percent ...
DUBLIN, Ireland, Aug. 07, 2018-- Avadel Pharmaceuticals plc, a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced its ...
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Avadel Pharmaceuticals plc (AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018, before the market open. For more information, please visit www.avadel.com.
This analysis is intended to introduce important early concepts to people who are starting to invest and looking to gauge the potential return on investment in Avadel Pharmaceuticals plc (NASDAQ:AVDL).Read More...
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on CASI sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
The Dublin-based company said it had a loss of 32 cents per share. The specialty pharmaceutical company posted revenue of $33.3 million in the period. Avadel expects full-year revenue in the range of $105 ...
In December 2017, Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its latest earnings update, which confirmed that the business finally turned profitable after delivering negative earnings on average over the last coupleRead More...
Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) in a Monday report. The Analyst Analyst David Risinger upgraded shares of Jazz ...